全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Vogt-Koyanagi-Harada (VKH) Disease

DOI: 10.4236/ojcd.2024.143003, PP. 25-35

Keywords: VKH Syndrome, VKH Disease, Vogt Koyanagi Harada

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: Vogt-Koyanagi-Harada (VKH) disease is a rare, multisystem autoimmune disorder characterized by bilateral granulomatous panuveitis, with or without extraocular manifestations. Although its exact etiology and pathogenesis remain unclear, it is hypothesized to involve T-cell dysregulation targeting melanocyte-containing tissues, including the CNS, eye, ear, and skin. VKH predominantly affects pigmented groups, such as Asians, Hispanics, Indians, Native Americans, and Mediterranean ethnicities, accounting for 7-22.4% of uveitis cases. Retrospective analyses indicate a higher incidence among female patients, with most cases occurring in the second and fifth decades of life. Aim: This case report discusses a patient with probable VKH who exhibited ocular, neurologic, and auditory symptoms typical of the prodromal or acute uveitic phase and responded well to prompt management. Case Presentation: A young female in her late 20s presented with low-grade fever, severe headache, neck pain, and neck stiffness. She had received symptomatic treatment at another hospital without relief. She was empirically started on intravenous antibiotics and dexamethasone for suspected pyogenic meningitis and was discharged upon symptom relief. However, she returned two days later due to symptom recurrence. Ophthalmic examination revealed decreased visual acuity bilaterally (6/24), sluggish pupil reaction, optic disc edema, and bilateral macular serous detachments. Mild vitritis with anterior chamber cells and iris pigment on the anterior lens capsule was noted in the left eye. Systemic examination was unremarkable, except for fine crepitations in the bilateral lower lung fields. Management: Considering VKH disease, the patient was started on intravenous methylprednisolone pulse therapy (1 gram/day) for 3 days, followed by oral steroids and topical steroid drops for the eyes. She was discharged with oral prednisolone and prednisolone acetate 1% eye drops. At follow-up, her vision improved, and there was resolution of papillitis and serous retinal detachments. Conclusions: VKH is a significant cause of bilateral vision loss. This case of probable VKH syndrome underscores the importance of early recognition and aggressive treatment in achieving a favorable visual prognosis.

References

[1]  Rahman, N., Artiaga, J.C.M., Bouras, K., Luis, J., Rees, A. and Westcott, M. (2023) Immunosuppressive Therapy for Vogt-Koyanagi-Harada Disease: A Retrospective Study and Review of Literature. Journal of Ophthalmic Inflammation and Infection, 13, Article No. 27.
https://doi.org/10.1186/s12348-023-00333-6
[2]  Sharma, S., Patil, Y., Garg, R., Rajguru, J., Sirsalmath, M., Bevinakatti, V., et al. (2020) Vogt-Koyanagi-Harada (VKH) Syndrome: A New Perspective for Healthcare Professionals. Journal of Family Medicine and Primary Care, 9, 31-35.
https://doi.org/10.4103/jfmpc.jfmpc_787_19
[3]  Baltmr, A., Lightman, S. and Tomkins-Netzer, O. (2016) Vogt-Koyanagi-Harada Syndrome—Current Perspectives. Clinical Ophthalmology, 10, 2345-2361.
https://doi.org/10.2147/opth.s94866
[4]  Fouad, Y., Mekkawy, M., Nowara, M. and Aziz, I. (2023) Clinical and Multimodal Imaging Characteristics of Eyes with Vogt-Koyanagi-Harada Disease: An Egyptian Experience. Oman Journal of Ophthalmology, 16, 88-93.
https://doi.org/10.4103/ojo.ojo_376_21
[5]  Al-Halafi, A., Dhibi, H.A., Hamade, I.H., Bou Chacra, C.T. and Tabbara, K.F. (2011) The Association of Systemic Disorders with Vogt-Koyanagi-Harada and Sympathetic Ophthalmia. Graefes Archive for Clinical and Experimental Ophthalmology, 249, 1229-1233.
https://doi.org/10.1007/s00417-011-1727-4
[6]  Tugal-Tutkun, I., Ozyazgan, Y., Akova, Y.A., Sullu, Y., Akyol, N., Soylu, M., et al. (2006) The Spectrum of Vogt-Koyanagi-Harada Disease in Turkey. International Ophthalmology, 27, 117-123.
https://doi.org/10.1007/s10792-006-9001-1
[7]  Murthy, S.I., Moreker, M.R., Sangwan, V.S., Khanna, R.C. and Tejwani, S. (2007) The Spectrum of Vogt-Koyanagi-Harada Disease in South India. International Ophthalmology, 27, 131-136.
https://doi.org/10.1007/s10792-007-9046-9
[8]  Shu, Q., Yang, P., Hou, S., Li, F., Chen, Y., Du, L., et al. (2010) Interleukin-17 Gene Polymorphism Is Associated with Vogt-Koyanagi-Harada Syndrome but Not with Behçet’s Disease in a Chinese Han Population. Human Immunology, 71, 988-991.
https://doi.org/10.1016/j.humimm.2010.06.020
[9]  Chee, S., Jap, A. and Bacsal, K. (2006) Spectrum of Vogt-Koyanagi-Harada Disease in Singapore. International Ophthalmology, 27, 137-142.
https://doi.org/10.1007/s10792-006-9009-6
[10]  Lavezzo, M.M., Sakata, V.M., Morita, C., Rodriguez, E.E.C., Abdallah, S.F., da Silva, F.T.G., et al. (2016) Vogt-Koyanagi-Harada Disease: Review of a Rare Autoimmune Disease Targeting Antigens of Melanocytes. Orphanet Journal of Rare Diseases, 11, Article No. 29.
https://doi.org/10.1186/s13023-016-0412-4
[11]  Silpa-Archa, S., Silpa-archa, N., Preble, J.M. and Foster, C.S. (2016) Vogt-Koyanagi-Harada Syndrome: Perspectives for Immunogenetics, Multimodal Imaging, and Therapeutic Options. Autoimmunity Reviews, 15, 809-819.
https://doi.org/10.1016/j.autrev.2016.04.001
[12]  Moorthy, R.S., Inomata, H. and Rao, N.A. (1995) Vogt-Koyanagi-Harada Syndrome. Survey of Ophthalmology, 39, 265-292.
https://doi.org/10.1016/s0039-6257(05)80105-5
[13]  EyeWiki (2023) Vogt-Koyanagi-Harada Disease.
https://eye-wiki.aao.org/Vogt-Koyanagi-Harada_Disease
[14]  Mondkar, S. (2000) Analysis of 87 Cases with Vogt-Koyanagi-Harada Disease. Japanese Journal of Ophthalmology, 44, 296-301.
https://doi.org/10.1016/s0021-5155(00)00152-0
[15]  Agrawal, R., Xin, W., Keane, P.A., Chhablani, J. and Agarwal, A. (2016) Optical Coherence Tomography Angiography: A Non-Invasive Tool to Image End-Arterial System. Expert Review of Medical Devices, 13, 519-521.
https://doi.org/10.1080/17434440.2016.1186540
[16]  Aggarwal, K., Agarwal, A., Mahajan, S., Invernizzi, A., Mandadi, S.K.R., Singh, R., et al. (2016) The Role of Optical Coherence Tomography Angiography in the Diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease. Ocular Immunology and Inflammation, 26, 142-153.
https://doi.org/10.1080/09273948.2016.1195001
[17]  Lai, T.Y.Y., Chan, R.P.S., Chan, C.K.M. and Lam, D.S.C. (2008) Effects of the Duration of Initial Oral Corticosteroid Treatment on the Recurrence of Inflammation in Vogt-Koyanagi-Harada Disease. Eye, 23, 543-548.
https://doi.org/10.1038/eye.2008.89
[18]  Hosoda, Y., Hayashi, H. and Kuriyama, S. (2015) Posterior Subtenon Triamcinolone Acetonide Injection as a Primary Treatment in Eyes with Acute Vogt-Koyanagi-Harada Disease. British Journal of Ophthalmology, 99, 1211-1214.
https://doi.org/10.1136/bjophthalmol-2014-306244
[19]  Paredes, I., Ahmed, M. and Foster, C.S. (2006) Immunomodulatory Therapy for Vogt-Koyanagi-Harada Patients as First-Line Therapy. Ocular Immunology and Inflammation, 14, 87-90.
https://doi.org/10.1080/09273940500536766
[20]  Urzua, C.A., Velasquez, V., Sabat, P., Berger, O., Ramirez, S., Goecke, A., et al. (2015) Earlier Immunomodulatory Treatment Is Associated with Better Visual Outcomes in a Subset of Patients with Vogt‐Koyanagi‐Harada Disease. Acta Ophthalmologica, 93, e475-e480.
https://doi.org/10.1111/aos.12648
[21]  Yeh, S., Huang, Y. and Thomas, J. (2022) Innovations in the Diagnosis and Management of Uveitis: Promising Research to Address Unmet Patient Needs. Annals of Eye Science, 7, 1-1.
https://doi.org/10.21037/aes-21-54
[22]  Anthony, E., Rajamani, A., Baskaran, P. and Rajendran, A. (2022) Vogt Koyanagi Harada Disease Following a Recent COVID-19 Infection. Indian Journal of Ophthalmology, 70, 670-672.
https://doi.org/10.4103/ijo.ijo_2550_21
[23]  Yepez, J.B., Murati, F.A., Petitto, M., De Yepez, J., Galue, J.M., Revilla, J., et al. (2021) Vogt-Koyanagi-Harada Disease Following COVID-19 Infection. Case Reports in Ophthalmology, 12, 804-808.
https://doi.org/10.1159/000518834

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133